Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

135.71 1.24 −0.91%
Market cap
$13.9B
P/E
19.2×
Fwd P/E
30.5×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
7 8 6 6 4 5 7 6 3 —
P/E ratio
29.43 40.38 51.86 74.58 89.65 21.98 268.73 324.59 0.00 0.00
P/S ratio
4.93 5.82 6.82 7.73 7.11 8.53 12.49 14.28 39.55 92.53
Altman Z-Score
7.80 8.83 8.70 11.59 7.62 9.70 8.65 7.24 7.56 35.68
Altman Z″-Score (non-manufacturers)
6.21 5.61 4.58 5.40 3.70 4.35 (0.12) 1.66 (0.97) (0.53)
P/FCF ratio
18.85 24.60 35.59 35.63 34.56 41.01 74.42 84.09 0.00 0.00
Beneish M-Score
(2.64) (2.23) (1.68) (2.15) (2.60) (1.55) (1.75) (1.52) — —
P/Operating CF
36.33 56.51 104.21 80.45 1,918.35 94.43 100.99 127.57 172.16 (106.00)
P/B ratio
4.34 5.29 5.77 6.74 5.86 7.92 15.46 13.40 18.77 10.65
Price to Tangible BV
4.35 5.37 5.86 6.89 5.86 7.92 15.46 13.40 18.77 10.65
EV/Sales
4.61 5.60 6.57 7.38 7.11 8.44 12.24 14.54 38.72 84.07
EV/EBITDA
20.71 23.07 48.80 40.97 58.40 45.72 96.46 109.92 0.00 0.00
EV/Operating CF
16.85 22.14 31.78 32.39 31.44 38.62 65.62 64.72 (72.50) (28.69)
EV/FCF
17.61 23.66 34.27 34.04 34.60 40.55 72.91 85.67 (67.54) (27.62)
Quick Ratio
2.92 3.06 2.25 2.49 3.65 5.14 1.41 8.03 10.05 10.11
Current Ratio
3.39 3.40 2.45 2.70 3.96 5.45 1.47 8.36 10.20 10.21
Net Debt/EBITDA
(2.33) (1.88) (4.06) (3.69) (2.72) (2.50) (5.83) (4.40) 1.27 2.15
Debt/Assets
0.00% 0.00% 0.00% 0.00% 16.17% 18.33% 6.66% 39.12% 45.21% 0.17%
Debt/Equity
0.00 0.00 0.00 0.00 0.24 0.28 0.14 0.81 0.99 0.00
Asset Turnover
0.69 0.68 0.67 0.67 0.60 0.69 0.69 0.50 0.27 0.04
Operating CF/Net income
1.64 1.74 1.56 2.20 2.86 0.56 3.97 4.81 0.66 0.75
Capex/Depreciation
(1.95) (42.44) (9.43) (0.85) (0.66) (0.36) (0.53) (1.08) (0.43) (0.82)
Interest Coverage
— — 54.54 35.07 3.97 4.97 2.26 1.21 (6.73) (49.12)
ROE
16.38% 14.16% 12.68% 10.03% 7.17% 46.20% 6.62% 4.95% (41.50%) (38.17%)
ROA
11.46% 9.79% 8.89% 6.96% 4.71% 26.79% 3.22% 2.33% (24.10%) (33.60%)
ROIC
21.83% 23.56% 13.06% 21.66% 6.42% 15.84% 84.62% 10.53% (36.36%) (1,130.99%)
Return on Tangible Assets
25.61% 26.26% 24.41% 15.86% 11.41% 46.59% 12.03% 3.09% (27.88%) (49.28%)
Average Days of Receivables
87.64 74.25 84.97 85.81 59.73 54.83 58.63 46.44 70.29 0.00
Research and Development Expense of Revenue
35.51% 31.04% 29.94% 31.15% 28.95% 26.29% 25.38% 34.53% 56.81% 628.61%
Selling, General and Administrative Expense of Revenue
40.42% 42.76% 47.04% 50.56% 51.46% 41.43% 44.93% 55.16% 105.12% 453.87%
Intangible Assets out of Total Assets
0.00 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
7.62% 8.30% 10.30% 11.63% 11.84% 9.56% 9.55% 12.88% 26.31% 189.76%
Graham Net Nets
0.08 0.04 0.05 0.07 0.03 0.05 0.02 0.04 0.02 0.08
Graham Number
59.55 44.29 36.13 25.41 17.62 34.45 7.91 5.14 0.00 0.00
Earnings Yield
3.40% 2.48% 1.93% 1.34% 1.12% 4.55% 0.37% 0.31% (2.06%) (4.19%)
Free Cash Flow Yield
5.31% 4.07% 2.81% 2.81% 2.89% 2.44% 1.34% 1.19% (1.45%) (3.29%)
Revenue per Share
28.75 23.46 19.32 15.54 11.98 11.23 8.60 5.00 1.83 0.17
Operating CF per Share
7.87 5.93 3.99 3.54 2.71 2.45 1.60 1.12 (1.07) (1.22)
Capex per Share
(0.34) (0.38) (0.29) (0.17) (0.25) (0.12) (0.16) (0.27) (0.08) (0.05)
Free Cash Flow per Share
7.52 5.55 3.70 3.37 2.46 2.34 1.44 0.85 (1.15) (1.27)
Cash per Share
14.88 10.72 10.56 10.33 7.52 8.60 7.32 7.22 5.86 3.54
Shareholders Equity per Share
32.69 25.79 22.85 17.83 14.52 12.10 6.95 5.33 4.22 3.63
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
32.69 25.79 22.85 17.83 14.52 12.10 6.95 5.33 4.22 3.63
Free Cash Flow
748.70 557.20 361.60 322.90 233.10 217.60 132.30 76.60 (101.26) (110.28)
Working Capital
1,779.30 1,217.00 952.20 915.80 727.00 829.70 265.70 649.54 500.49 280.03
Capital Expenditures
(34.00) (38.20) (28.30) (16.50) (23.40) (10.90) (14.70) (24.80) (6.93) (4.09)
Net Current Asset Value
1,144.30 595.70 587.60 792.60 274.30 407.70 161.90 225.39 109.47 260.23
EV/EBIT
21.30 23.11 49.39 44.14 78.68 54.14 133.42 178.33 0.00 0.00
Capex to Sales
0.01 0.02 0.02 0.01 0.02 0.01 0.02 0.06 0.04 0.27
Price to Operating Income
22.79 24.02 51.30 46.20 78.61 54.75 136.18 175.03 0.00 0.00
Other line items
Depreciation/Fixed assets
0.19 0.01 0.04 0.33 0.61 0.67 0.66 0.68 1.47 0.79
Cash ROIC
15.82% 15.20% 11.08% 11.97% 9.63% 9.69% 9.49% 5.04% (8.05%) (17.71%)
Accounts Receivable Turnover
4.91 5.13 4.78 5.56 6.62 7.37 8.57 10.19 7.15 0.00
Accounts Payable Turnover
0.09 0.07 0.10 0.08 0.07 0.07 0.07 0.07 0.03 0.00
Inventory Turnover
0.82 0.71 1.08 0.71 0.49 0.45 0.53 0.82 0.21 —
Average Days of Payables
4,723.98 4,955.41 4,126.25 5,468.71 5,763.43 6,096.58 6,969.53 6,434.21 15,577.99 0.00
Days of Inventory on Hand
483.40 616.21 352.13 552.22 778.50 1,011.88 853.31 809.26 298.05 —
Average Receivables
582.95 459.20 394.65 267.75 171.30 141.85 92.00 44.27 22.61 —
Average Payables
567.95 455.20 398.20 286.70 197.25 155.00 113.84 69.95 39.85 14.37
Average Inventory
63.20 47.85 36.70 32.80 29.25 22.65 14.08 5.94 6.01 —
Average Assets
4,175.10 3,485.05 2,810.05 2,220.60 1,903.60 1,520.35 1,149.58 905.37 591.34 419.94
Average Common Equity
2,921.40 2,410.85 1,969.90 1,540.90 1,250.10 881.55 558.83 426.45 343.51 369.67

Fold the line items

Columns are period end dates